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Osteoarthritis (OA) is themost frequent joint disorder and an important cause of disability. Recent studies have shown the potential
of adipose-tissue-derived mesenchymal stem cells (AD-MSC) for cartilage repair. We have investigated whether conditioned
medium from AD-MSC (CM) may regulate in OA chondrocytes a number of key mediators involved in cartilage degeneration.
CM enhanced type II collagen expression in OA chondrocytes while decreasing matrix metalloproteinase (MMP) activity in cell
supernatants as well as the levels ofMMP-3 andMMP-13 proteins andmRNA inOA chondrocytes stimulated with interleukin- (IL-
) 1𝛽. In addition, CM increased IL-10 levels and counteracted the stimulating effects of IL-1𝛽 on the production of tumor necrosis
factor-𝛼, IL-6, prostaglandin E
2
, and NOmeasured as nitrite and the mRNA expression of these cytokines, CCL-2, CCL-3, CCL-4,
CCL-5, CCL-8, CCL-19, CCL-20, CXCL-1, CXCL-2, CXCL-3, CXCL-5, CXCL-8, cyclooxygenase-2, microsomal prostaglandin E
synthase-1, and inducible NO synthase. These effects may be dependent on the inhibition of nuclear factor-𝜅B activation by CM.
Our data demonstrate the chondroprotective actions of CMand provide support for further studies of this approach in joint disease.
1. Introduction
Osteoarthritis (OA) is a leading cause of disability in the
elderly and has a significant impact on health care (reviewed
in [1]). Although the pathogenesis of OA remains unclear, the
chronic production of different mediators by articular tissues
is believed to contribute to tissue degradation. Levels of
proinflammatory cytokines such as interleukin- (IL-) 1𝛽 and
tumor necrosis factor-𝛼 (TNF𝛼) are elevated in the inflamed
synovium in OA, accompanied by the increased expression
of their receptors and decreased levels of inhibitory proteins.
These cytokines mediate cartilage destruction through the
upregulation of inflammatory or catabolic genes and the
downregulation of anti-inflammatory or anabolic genes in
articular chondrocytes (reviewed in [2]). In particular, IL-1𝛽
reduces the expression of type II collagen [3] and increases
the production of matrix metalloproteinases (MMPs) [4, 5],
prostaglandin E
2
(PGE
2
), cytokines, chemokines, reactive
oxygen species, and nitric oxide (NO) [6, 7]. Chondrocytes
are the main source of NO in OA articular tissues and the
oxidative stress caused by this mediator has been related to
degeneration in arthritic joints [8]. Therefore, NO can play a
role in IL-1𝛽-induced suppression of glycosaminoglycan and
collagen synthesis, expression of MMPs, and activation of
proenzymes [9].
Mesenchymal stem cells (MSC) are being investigated
as a possible cell-based therapy for late stages of OA [10].
Some promising results have been obtained in a pilot study
of knee OA using autologous bone-marrow-derived mes-
enchymal stem cells [11]. Interestingly, stem cells are able
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to secrete a wide range of trophic mediators that can exert
paracrine effects on other cell types. Therefore, stem-cell-
conditioned media have shown potential therapeutic appli-
cations in neural, myocardial, and osteogenic regeneration
or in wound healing (reviewed in [12]). Adipose-tissue-
derived mesenchymal stem cells (AD-MSC) are extensively
investigated for tissue regeneration or immunomodulation
(reviewed in [13, 14]). Interestingly, stem cells are able to
secrete a wide range of trophic mediators that can exert
paracrine effects on other cell types. In this study, we have
examined the potential of the conditioned medium from
basal AD-MSC (CM) to regulate type II collagen expression
and the production of relevant mediators involved in OA
articular degeneration using OA chondrocytes in primary
cultures as an in vitro model to study inflammatory and
degradative responses [15].
2. Materials and Methods
2.1. Cells and Culture Media. Adipose tissues were obtained
from 11 donors who had undergone abdominoplasty without
any underlying diseases. Adipose tissue samples were washed
with phosphate-buffered saline (PBS), minced, digested at
37∘C for 1 h with 2% of type I collagenase (Gibco, Life
Technologies, Madrid, Spain), and filtered through a 100 𝜇m
cell strainer (BD Biosciences Durham, NC, USA). The cells
were washed with DMEM/HAM F12 containing penicillin
and streptomycin (1%), seeded onto tissue culture flasks in
DMEM/HAM F12 medium with penicillin and streptomycin
(1%) supplemented with 15% human serum, and incubated
with 5% CO
2
at 37∘C. Human serum was obtained from
whole-blood donations of AB-blood-group-typed donors
according to the criteria of Valencia Transfusion Center.
At 24 h, when the cells reached the semiconfluence, the
tissue culture plates were washed to remove any residual
nonadherent cells. The phenotype of AD-MSC was analyzed
by flow cytometry (Flow Cytometer II, BD Biosciences, San
Jose, CA,USA)with specific antibodies, anti-CD105-PE, anti-
CD90PerCP-eFluo 710, anti-CD34APC (eBioscience, Inc.,
San Diego, CA, USA), and anti-CD45-PE (BD Pharmigen)
and cellular viability with propidium iodide. CM was col-
lected from cells at passages 0 and 1 every 48 h of culture,
pooled, centrifuged, and stored at−80∘C in sterile conditions.
The knee specimens were obtained from patients with
the diagnosis of advanced OA (22 women and 8 men, aged
72.1 ± 7.8 years, mean ± S.E.M.) undergoing total knee joint
replacement. Diagnosis was based on clinical, laboratory,
and radiological evaluation. Cartilage was dissected from
the femoral condyles and tibial plateau of the knee joint
and diced into small pieces. Human articular chondrocytes
were isolated by sequential enzymatic digestion: 1 h with
0.1mg/mL hyaluronidase (Sigma-Aldrich) followed by 12–
15 h with 2mg/mL collagenase (type IA) (Sigma-Aldrich)
in DMEM/HAM F12 (Sigma-Aldrich) containing penicillin
and streptomycin (1%) at 37∘C in 5% CO
2
atmosphere. The
digested tissue was filtered through a 70 𝜇m nylon mesh
(BD Biosciences), washed, and centrifuged. Cell viability was
greater than 95% according to the Trypan blue exclusion
test. All experiments were performed with chondrocytes in
primary cultures at semiconfluence (270×103 cells/well in 6-
well plates or 1.5 × 106 cells in 3.5 cm plates). Chondrocytes
were maintained with 5% CO
2
at 37∘C in DMEM/HAM
F12 (Sigma-Aldrich) containing penicillin and streptomycin
(1%), supplemented with 10% fetal bovine serum (Sigma-
Aldrich). For cell stimulation, chondrocytes were incubated
for 24 h or 5 days in DMEM/HAM F12 (Sigma-Aldrich)
containing penicillin and streptomycin (1%) supplemented
with 10% human serum, in the presence or absence of IL-1𝛽
(10 ng/mL) and/or CM (1mL of medium for 6-well plates or
2 mL for 3.5 cm plates).
The design of the work was approved by the Institutional
Ethical Committees (University of Valencia and University
Clinical Hospital, Valencia, Spain). Samples were obtained
from donors after they provided informed consent according
to the Helsinki Declaration of 1975, as revised in 2008.
2.2. MTT Assay. The mitochondrial dependent reduction
of 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bro-
mide (MTT) to formazan was assayed in OA chondrocytes
incubated with IL-1𝛽 (10 ng/mL) or IL-1𝛽 (10 ng/mL) + CM
for 24 h or 5 days. The cells were then incubated with MTT
(200𝜇g/mL) for 2 h. The medium was removed and the cells
were solubilized in dimethyl sulfoxide (100 𝜇L) to quantitate
formazan at 550 nm [16].
2.3. Immunocytochemistry. Chondrocytes were seeded at
20 × 103 cells/well in Lab-tek chambers (Thermo Scientific,
Rochester, NY, USA) and stimulated with IL-1𝛽 (10 ng/mL)
or IL-1𝛽+CM for 5 days. Cells were fixed with 4% formalde-
hyde in PBS for 30min at 4∘C and incubated with rabbit
anti-human type II collagen polyclonal antibody (Chemi-
con/Millipore, Schwalbach, Germany). Finally, chondrocytes
were incubatedwith goat anti-rabbit IgG-FITC (R&DBiosys-
tems, Abingdon, UK). Slides were mounted in Prolong Gold
antifade reagent with DAPI (Molecular Probes, Invitro-
gen, Life Technologies) and examined under a fluorescence
microscope (Leica DM IL LED, Solms, Germany). Cells were
counted in 6microscopic fields of each well.Thereby collagen
II-positive cells were determined as a percentage of total cell
number.
2.4. Determination of MMP Activity. Chondrocytes were
stimulated with IL-1𝛽 (10 ng/mL) or IL-1𝛽+CM for 24 h or
5 days and supernatants were harvested, centrifuged, and
incubated with p-aminophenylmercuric acetate for 12 h at
37∘C to activate MMPs. Aliquots of supernatants were then
transferred to a 96-well plate and after addition of the 5-
FAM peptide substrate (AnaSpec Inc., San Jose, CA, USA),
fluorescence was measured for different times at 490 nm
(excitation)/520 nm (emission) in aVictor3microplate reader
(PerkinElmer Espan˜a, Madrid, Spain).
2.5. Enzyme-Linked Immunosorbent Assay. Chondrocytes
were stimulated with IL-1𝛽 (10 ng/mL) or IL-1𝛽+CM for 24 h
or 5 days. Supernatants were harvested, centrifuged, and
frozen at −80∘C until analysis. TNF𝛼, IL-6, and IL-10 were
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Figure 1: Effects of CM on (a) cell proliferation and (b) MMP activity in OA chondrocytes. (a) Cell proliferation was measured by the MTT
method. Results are expressed as % MTT with respect to nonstimulated cells at 24 h. (b) MMP activity was measured by fluorometry in cell
culture supernatants after 24 h or 5 days of incubation of chondrocytes in the presence or absence of IL-1𝛽 and CM. Activity is expressed as
fluorescence units (FU) per mg of protein. Data represent mean ± S.E.M. of independent cultures with chondrocytes from 4 different donors.
++𝑃 < 0.01 with respect to nonstimulated cells; ∗∗𝑃 < 0.01 with respect to IL-1𝛽; ##𝑃 < 0.01 with respect to the corresponding group after
24 h incubation.
measured by enzyme-linked immunosorbent assay (ELISA)
kits from eBioscience (San Diego, CA, USA) with sensitivity
of 4.0 pg/mL for TNF𝛼 and IL-6 and 2.0 pg/mL for IL-10.
MMP-3 and MMP-13 proteins were measured by ELISA
kits (eBioscience) with sensitivity of 8.0 and 18.0 pg/mL,
respectively. Nuclear factor-𝜅B (NF-𝜅B) binding to DNAwas
quantified by ELISA in nuclear extracts from cells stimulated
with IL-1𝛽 (10 ng/mL) in the presence or absence of CM for
1 h, using the Nuclear Extract Kit Active Motif for nuclei
extraction followed by TransAM NF-𝜅B kit (Active Motif
Europe, Rixensart, Belgium), according to themanufacturer’s
recommendations.
2.6. Real-Time PCR. Total RNA was extracted using the
TriPure reagent (Roche Applied Science, Barcelona, Spain)
according to the manufacturer’s instructions. Reverse tran-
scription was accomplished on 1𝜇g of total RNA using
random primers (TaqMan reverse transcription reagents,
Applied Biosystems, Madrid, Spain). PCR assays were per-
formed in duplicate on an iCycler Real-Time PCR Detec-
tion System using SYBR Green PCR Master Mix (Bio-Rad
Laboratories, Richmond, CA, USA). Sequences of primers
used have been reported previously [17–21] and were syn-
thesized by Eurofins MWG Operon (Ebersberg, Germany).
Some primer sets were from SA Biosciences Corporation
(Tebu-Bio, Barcelona, Spain). For each sample, differences in
threshold cycle (ΔCt) values were calculated by correcting the
Ct of the gene of interest to the Ct of the reference gene 𝛽-
actin. Relative gene expression was expressed as 2−ΔΔCt with
respect to nonstimulated cells.
2.7. Determination of NO and PGE
2
. Chondrocytes were
stimulated with IL-1𝛽 (10 ng/mL) or IL-1𝛽+CM for 24 h or
5 days. Supernatants were used to measure prostaglandin
E
2
(PGE
2
) by radioimmunoassay [22] and nitrite by a
fluorometric method [23] using a Victor3 microplate reader
(PerkinElmer Espan˜a, Madrid, Spain).
2.8. Statistical Analysis. The data were analyzed by one-way
analysis of variance (ANOVA) followed by Bonferroni’s
posttest using the GraphPad Prism 5 software (GraphPad
Software, La Jolla, CA, USA). A 𝑃 value of less than 0.05 was
considered to be significant.
3. Results
3.1. Cell Proliferation. To determine whether CM treatment
affected OA chondrocyte proliferation, OA chondrocytes
were incubated in the absence or presence of CM and IL-
1𝛽. After 24 h or 5 days, the MTT reaction was performed.
As shown in Figure 1(a), a significantly higher MTT %
was observed for all groups after 5 days with respect to
24 h incubation. The presence of CM did not induce any
significant changes in cell proliferation.
3.2. Effects on Matrix Metalloproteinases. MMPs are key
mediators in cartilage degradation. To characterize the effects
of CM on OA chondrocytes, we measured MMP activity as
well as the levels of MMP-3 and MMP-13 proteins in cell
supernatants. In addition, we determined mRNA expression
in OA chondrocytes. IL-1𝛽 enhanced the MMP activity
present in cell supernatants after 24 h of incubation and to
a greater extent after 5 days (Figure 1(b)). Interestingly, MMP
activity was significantly reduced by CM at both time points.
MMP-3 protein (Figure 2(a)) and mRNA (Figure 2(c)) levels
were decreased by CM in IL-1𝛽-stimulated chondrocytes and
this effect was significant after 24 h of incubation. Figure 2(b)
shows that MMP-13 protein levels were reduced by CM after
IL-1𝛽 stimulation (24 h and 5 days of incubation). MMP-13
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Figure 2: Effects of CM on MMP-3 (a) and MMP-13 (b) proteins and mRNA (c) expression in OA chondrocytes. (a, b) Protein levels were
measured by ELISA in cell supernatants after 24 h or 5 days of incubation of chondrocytes in the presence or absence of IL-1𝛽 and CM. (c)
mRNA expression was determined by real-time PCR analysis in OA chondrocytes after 24 h of incubation in the presence or absence of IL-1𝛽
and CM. Results indicate relative expression with respect to nonstimulated OA chondrocytes. Data represent mean ± S.E.M. of independent
cultures with chondrocytes from 4 different donors. +𝑃 < 0.05, ++𝑃 < 0.01 with respect to nonstimulated cells; ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 with
respect to IL-1𝛽; ##𝑃 < 0.01 with respect to the corresponding group after 24 h incubation.
mRNA expression was also significantly reduced by CM in
IL-1𝛽-stimulated OA chondrocytes (Figure 2(c)).
3.3. Effects on Collagen II Expression. Collagen II is a marker
of articular chondrocyte functionality. Figure 3(a) shows a
representative image of collagen II expression in OA chon-
drocytes in the presence or absence of IL-1𝛽 and CM after
5 days of incubation. This cytokine reduced the expression
of collagen II, but CM significantly increased the percentage
of collagen II-positive cells either in basal conditions or in
chondrocytes stimulated with IL-1𝛽 (Figure 3(b)).
3.4. Effects on Cytokines and Chemokines. IL-6 and TNF𝛼
are key mediators of the inflammatory response and were
measured in supernatants by ELISA. Figure 4(a) shows that
IL-1𝛽 strongly increased IL-6 levels in cell supernatants
after 24 h or 5 days of incubation whereas CM significantly
decreased the production of IL-6 at both time points. In
addition, the levels of TNF𝛼 induced by IL-1𝛽 were reduced
by CM after 24 h incubation (Figure 4(b)). Interestingly, the
production of the anti-inflammatory cytokine IL-10 was sig-
nificantly enhanced by CM at both time points (Figure 4(c)).
The results on mRNA expression paralleled the effects of
CM on protein levels. Therefore, we observed a reduced
expression of IL-6 and TNF𝛼 while IL-10 mRNA expression
was significantly enhanced by CM in IL-1𝛽-stimulated chon-
drocytes (Figure 4(d)). In OA, there is an increased expres-
sion of chemokines in chondrocytes under the influence
of inflammatory cytokines such as IL-1𝛽 [24, 25]. Figure 5
shows that IL-1𝛽 enhanced the mRNA expression of CCL-
2, CCL-3, CCL-4, CCL-5, CCL-8, CCL-19, CCL-20, CXCL-
1, CXCL-2, CXCL-3, CXCL-5, and CXCL-8 after 24 h of
incubation.When CMwas included in the incubationmedia,
we observed a significant reduction in the expression of these
chemokines.
3.5. Production of NO and PGE
2
. We also investigated the
production of other relevant mediators in our experimental
system. The concentrations of nitrite, as an index of NO
production, and PGE
2
were measured in the supernatant
of OA chondrocytes after 24 h or 5 days of incubation. The
presence of CM during the incubation period resulted in
a significant reduction in the levels of nitrite (Figure 6(a))
and PGE
2
(Figure 6(b)) in the supernatant at both time
points in the presence of IL-1𝛽 stimulation. We analyzed the
relative mRNA expression of inducible NO synthase (iNOS),
cyclooxygenase-2 (COX-2), and microsomal PGE synthase-1
(mPGES-1) in OA chondrocytes incubated with IL-1𝛽 and/or
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Figure 3: Immunocytochemical analysis of collagen II expression. Chondrocytes were treated with CM and/or IL-1𝛽 for 5 days. (a)
Representative image showing the expression of collagen II (FITC-immunofluorescence, green) and DAPI (blue) for cellular nuclei. Original
magnification ×200. (b) Percentages of collagen II-positive cells with respect to total cell numbers. Data represent mean ± S.E.M. of
independent cultures with chondrocytes from 4 different donors. +𝑃 < 0.05, ++𝑃 < 0.01 with respect to nonstimulated cells; ∗∗𝑃 < 0.01
with respect to IL-1𝛽.
CM for 24 h. Figure 6(c) shows that CM significantly reduced
the expression of iNOS thus leading to reduced nitrite
production, in addition to the downregulation of COX-2 and
mPGES-1 which would explain the inhibitory effects of CM
on PGE
2
.
3.6. NF-𝜅B Activation. To understand the mechanism
involved in the effects of CM on inflammatory and catabolic
mediators, we investigated the possible regulation of this
key transcription factor. IL-1𝛽 quickly induces NF-𝜅B
translocation into the nucleus and DNA binding to activate
gene transcription. Figure 7 shows the enhancement of p65-
NF-𝜅B-DNA binding induced by IL-1𝛽 in OA chondrocytes.
In the presence of CM, p65-NF-𝜅B binding to DNA was
significantly decreased.
4. Discussion
Several lines of evidence have demonstrated in OA artic-
ular tissues the production of a wide range of catabolic
and proinflammatory mediators leading to cartilage matrix
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Figure 4: Effects of CM on the protein levels of IL-6 (a), TNF𝛼 (b), and IL-10 (c) in supernatants and mRNA expression in OA chondrocytes
(d). (a–c) Cytokines were measured by ELISA in cell culture supernatants after 24 h or 5 days of incubation of chondrocytes with CM in the
presence or absence of IL-1𝛽. (d)mRNAexpressionwas determined by real-timePCRanalysis inOAchondrocytes after 24 h of incubation and
results indicate relative expression with respect to nonstimulated OA chondrocytes. Data represent mean ± S.E.M. of independent cultures
with chondrocytes from 6 different donors. ++𝑃 < 0.01 with respect to nonstimulated cells; ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 with respect to IL-1𝛽;
##𝑃 < 0.01 with respect to the corresponding group after 24 h incubation.
degradation (reviewed in [26]). In addition to other extra-
cellular matrix components, the fibrils of type II collagen are
essential for the integrity and survival of articular cartilage.
In OA cartilage, there is an upregulation of collagenases such
as MMP-13, the major type II collagen-degrading enzyme,
which initiate the denaturation of fibrillar type II collagen
thus contributing to the initiation and progression of joint
damage [27]. In this study, we have demonstrated that CM
enhances collagen II expression in nonstimulated OA chon-
drocytes and counteracts the negative effects of IL-1𝛽 on this
protein.We have also found that CMdownregulates catabolic
enzymes which play a key role in cartilage degradation.
Therefore, CM reduced the production of the collagenase
MMP-13 and to a lesser extent of the stromelysin MMP-3
whichmediates the direct degradation of extracellular matrix
components and the activation of other MMPs [28].
Proinflammatory cytokines activate chondrocytes lead-
ing to the synthesis and release of a wide range of mediators.
Our study reveals that CM downregulates the proinflam-
matory cytokines IL-6 and TNF𝛼 but upregulates the anti-
inflammatory cytokine IL-10. These effects are of relevance
for the progression of OA as proinflammatory cytokines
induce the synthesis of molecules contributing to the loss
of chondrocyte phenotype and cartilage degeneration [2].
In addition, the effect of CM on IL-10 may have positive
consequences on cartilage metabolism as this cytokine coop-
erates with other factors to inhibit cartilage breakdown in
experimental OA [29].
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Figure 5: Effects of CM on chemokine mRNA expression. mRNA expression was determined by real-time PCR analysis in OA chondrocytes
after 24 h of incubation in the presence or absence of IL-1𝛽 and/or CM. Results indicate relative expression with respect to nonstimulated OA
chondrocytes. Data represent mean ± S.E.M. of independent cultures with chondrocytes from 4 different donors. ++𝑃 < 0.01 with respect to
nonstimulated cells; ∗∗𝑃 < 0.01 with respect to IL-1𝛽.
Chondrocytes may amplify inflammatory and catabolic
responses through the release of chemokines promoting
inflammation, synovial angiogenesis [30, 31], and the pro-
duction of catabolic mediators such as MMPs in OA chon-
drocytes [32, 33]. Interestingly, CM reduced the expres-
sion of a number of chemokines relevant to chondrocyte
metabolism. Our data also show that CM counteracts NO
production in OA chondrocytes stimulated by IL-1𝛽. This
effect would be the consequence of iNOS downregulation
which may contribute to the protective actions of CM as NO
inhibits matrix synthesis [8]. In addition, we have shown the
inhibitory effects of CMonPGE
2
production.This eicosanoid
may contribute to cartilage degradation by promoting the
production of MMPs and inhibiting the synthesis of tissue
inhibitors of these enzymes [34, 35]. COX-2 and mPGES-
1 are functionally coupled and induced by IL-1𝛽 in OA
chondrocytes leading to an increased PGE
2
synthesis [36].
Therefore, the effect of CM on PGE
2
production by OA
chondrocytes may be relevant to cartilage metabolism and
would be dependent on the reduction of COX-2 andmPGES-
1 expression observed in our study.
The activation of NF-𝜅B plays a key role in the tran-
scription of iNOS, COX-2, MMPs, and different proinflam-
matory cytokines and chemokines [37, 38]. To understand
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Figure 6: Effects of CM on NO (a) and PGE
2
(b) production and iNOS, COX-2, and mPGES-1 mRNA (c) expression in OA chondrocytes.
(a) NO was measured by fluorometry as nitrite. (b) PGE
2
was measured by radioimmunoassay. Mediators were determined in cell culture
supernatants after 24 h or 5 days of incubation of OA chondrocytes with CM in the presence or absence of IL-1𝛽. (c) mRNA expression was
determined by real-time PCR analysis in OA chondrocytes after 24 h of incubation and results indicate relative expression with respect to
nonstimulated OA chondrocytes. Data represent mean ± S.E.M of independent cultures with chondrocytes from 6 (NO, PGE
2
) or 4 (mRNA)
different donors. ++𝑃 < 0.01 with respect to nonstimulated cells; ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 with respect to IL-1𝛽; ##𝑃 < 0.01 with respect to the
corresponding group after 24 h incubation.
the possible mechanism by which CM downregulates these
mediators, we have investigated its influence on NF-𝜅B. Our
results indicate that the observed inhibitory effects of CM on
the expression of catabolic and proinflammatory molecules
could be related to the reduction of NF-𝜅B activation in OA
chondrocytes stimulated with IL-1𝛽.
MSC have shown cytoprotective properties in experi-
mental models via paracrine mechanisms. The beneficial
effects of these cells may be related to the production of
different types of mediators such as cytokines and PGE
2
or a milieu of secreted factors exerting synergistic effects
[39–41]. Further studies are needed to elucidate the factors
responsible for the chondroprotective effects of CM or to
provide additional mechanistic insights.
5. Conclusion
The results of our study have shown the chondroprotective
role of CM by targeting catabolic and inflammatory medi-
ators and support the interest of this approach to search
for new treatments for inflammatory and/or degenerative
conditions of joints.
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